Search clinical trials for: TOLVAPTAN

Total 125 results

King's College Hospital NHS Trust

Recruiting

Low-dose Tolvaptan for Inpatient Hyponatraemia.

Hyponatremia | SIADH

United Kingdom
Chinese Pulmonary Vascular Disease Research Group

Recruiting

Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH

Pulmonary Arterial Hypertension | Randomized Controlled Trial

China
University Medical Center Groningen

Not yet recruiting

HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life (HYDRO-PROTECT)

ADPKD

Netherlands, United Kingdom, Belgium, Germany, France, Spain
Mayo Clinic
Hopital du Sacre-Coeur de Montreal

Recruiting

PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration (SerendipityPB1)

Autosomal Dominant Polycystic Kidney Disease | Nephrogenic Diabetes Insipidus | Acquired Nephrogenic Diabetes Insipidus | Congenital Nephrogenic Diabetes Insipidus

United States
National Cancer Institute (NCI)

Recruiting

GCC Agonist Signal in the Small Intestine

Gastroesophageal Reflux Disease | Barrett Esophagus | Malignant Digestive System Neoplasm

United States
Institute of Liver and Biliary Sciences, India

Recruiting

To Study Effect of the Combination of Midodrine and Tolvaptan Versus Tolvaptan Alone in Patients With Severe Hyponatremia in Cirrhosis(TOLMINA Trial)

Liver Cirrhosis

India
Otsuka Pharmaceutical Co., Ltd.

Recruiting

Samsca Post-marketing General Drug Use-results Survey in Patients With Hyponatremia in SIADH

Antidiuretic Hormone, Inappropriate Secretion

Japan
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Autosomal Recessive Polycystic Kidney Disease (ARPKD)

United States, Belgium, Spain, Germany, United Kingdom, Poland
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Autosomal Recessive Polycystic Kidney (ARPKD)

United States, United Kingdom, Belgium, Poland, France, Germany, Italy
Gia Dinh People Hospital
Otsuka Pharmaceutical Vietnam

Recruiting

Tolvaptan add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction (DR-AHF)

Acute Heart Failure

Vietnam
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia

United States
Korea Otsuka Pharmaceutical Co., Ltd.

Recruiting

Samsca PMS in ADPKD Patients

Safety

Korea, Republic of
Otsuka Pharmaceutical Co., Ltd.

Recruiting

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload

Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload

Japan
University of Cologne

Recruiting

The German ADPKD Tolvaptan Treatment Registry (AD(H)PKD)

ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Germany
National Cancer Institute (NCI)

Suspended

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Down Syndrome | Recurrent B Acute Lymphoblastic Leukemia

United States, Canada, Puerto Rico, Australia
McMaster University

Completed

Dietary Intervention in ADPKD on Tolvaptan (DIAT)

Polyuria | Autosomal Dominant Polycystic Kidney

Canada
Eli Lilly and Company

Active, not recruiting

A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India

Plaque Psoriasis | Psoriatic Arthritis

India
Otsuka Pharmaceutical Co., Ltd.

Completed

Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD

Polycystic Kidney, Autosomal Dominant

Japan
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Withdrawn

Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

Stage IIIA Non-Small Cell Lung Cancer

United States
Palladio Biosciences
Centessa Pharmaceuticals plc

Terminated

Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ALERT)

ADPKD | Polycystic Kidney Disease, Adult

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Germany, Italy, Belgium, United Kingdom
Mario Negri Institute for Pharmacological Research
Otsuka Pharmaceutical Italy S.r.l.

Completed

Tolvaptan-Octreotide LAR Combination in ADPKD (TOOL)

Autosomal Dominant Polycystic Kidney Disease

Italy
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease (ESSENTIAL)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Korea, Republic of
University of Chicago

Completed

Postoperative Tolvaptan Use in Left Ventricular Assist Device Implantation Patients (TOLVAD)

Heart Failure | Heart Assist Device | Hyponatremic

United States
University of North Carolina, Chapel Hill
Otsuka America Pharmaceutical

Completed

Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders (TROUPER)

Congestive Heart Failure

United States
Korea Otsuka Pharmaceutical Co., Ltd.

Terminated

Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites (ECF)

Hyponatremia and Extracellular Fluid in Cirrhotic

Korea, Republic of
Otsuka Pharmaceutical Development & Commercialization...

Completed

Tolvaptan Extension Study in Participants With ADPKD (TEMPO 4/4)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States, Australia, Belgium, Germany, Italy, Poland, Romania, United Kingdom, Argentina, Canada, France, Netherlands, Russian Federation
Otsuka Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure

Congestive Heart Failure

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure

Congestive Heart Failure

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study of OPC-41061 Orally Disintegrating (OD) Tablets Using 2 Different Formulations and 2 Dosing Regimens in Healthy Adult Male Subjects

Healthy Adult Male

Japan
The George Institute
University of Sydney

Terminated

Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial Magnetic Resonance Imaging Sub-study (TRIDENT-MRI)

Stroke | Hypertension | Cerebral Small Vessel Diseases | Vascular Dementia | Intracerebral Hemorrhage

Australia
Otsuka Pharmaceutical Co., Ltd.

Completed

A Multicenter, Open-label, Dose-finding Trial of OPC-41061 to Investigate Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety in Patients With Carcinomatous Edema (Phase 2)

Carcinomatous Edema

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH

Syndrome of Inappropriate Antidiuretic Hormone Secretion

Japan
M.D. Anderson Cancer Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Tolvaptan in Hyponatremic Cancer Patients

Advanced Cancers

United States
University of Calgary

Terminated

Tolvaptan for Advanced or Refractory Heart Failure

Heart Failure | Hyponatremia

Canada
Caleb Nelson
Otsuka America Pharmaceutical

Completed

TCUPS- Tolvaptan Use in Cystinuria and Urolithiasis: A Pilot Study (TCUPS)

Cystinuria

United States
Kyorin University

Unknown

Efficacy of Tolvaptan on ADPKD Patients

Autosomal Dominant Polycystic Kidney Disease

Japan
Otsuka Pharmaceutical Development & Commercialization...
Syneos Health

Terminated

An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Participants With Euvolemic or Hypervolemic Hyponatremia

Hyponatremia

Belgium, Spain, United States, United Kingdom, Italy, Germany, Czechia, Romania
Otsuka Pharmaceutical Development & Commercialization...

Completed

Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

Polycystic Kidney, Autosomal Dominant

Belgium, Germany, Italy, Spain, Sweden, United States, Canada, Australia, Netherlands, Czechia, Poland, Denmark, Israel, Hungary, Russian Federation, South Africa, United Kingdom, Romania, Argentina, Norway
Vanderbilt University

Completed

Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure

Heart Failure

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration

Chronic Renal Failure

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients

Heart Failure

Japan
University of Erlangen-Nürnberg Medical School

Completed

Tolvaptan Versus Fluid Restriction in SIADH

Hyponatremia | Pituitary | Syndrome of Inappropriate ADH (SIADH) Secretion
Assistance Publique - Hôpitaux de Paris
Otsuka Pharmaceutical Europe Ltd

Unknown

Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) (TOLVATHIRST)

Healthy Volunteers

France
University of Southern California
Otsuka America Pharmaceutical

Completed

Aquaresis Utility for Hyponatremic Acute Heart Failure Study (AQUA-AHF)

Heart Failure

United States
Michael Campos, MD
CSL Behring

Completed

Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.

Alpha 1 Antitrypsin Deficiency

United States
Brigham and Women's Hospital
Otsuka Pharmaceutical Co., Ltd.

Completed

The Role of Vasopressin Antagonism on Renal Sodium Handling

Healthy
Emory University

Completed

AiDing Diuresis wIth Tolvaptan (ADD-IT) (ADD-IT)

Congestive Heart Failure | Cardiomyopathy

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease

Netherlands
NYU Langone Health

Withdrawn

Fractional Urate Excretion in Nonedematous Hyponatremia

SIADH | Cerebral Hyponatremia | Cerebral Salt-wasting Syndrome | Reset Hypothalamic Osmostat

United States

Search clinical trials for: TOLVAPTAN

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations